Biogen Wins European Approval for MS Drug

7/25/11

Weston, MA-based Biogen Idec (NASDAQ: BIIBannounced today that it has received conditional approval from the European Commission to market the long-acting version of fampridine (Fampyra) to adult patients with multiple sclerosis (MS) who have walking disability. The drug was developed and commercialized in the United States by Hawthorne, NY-based Acorda Therapeutics (NASDAQ: ACOR). As part of the approval, the agency has asked Biogen to perform a study to assess the drug’s benefits beyond improving walking speed—a request that’s consistent with post-marketing research plans already in place, the company says.

By posting a comment, you agree to our terms and conditions.